You need to enable JavaScript to run this app.
The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated
Cookie Policy
Yes, I accept cookies
Steering Committee
About Us
Newsletter
Contact
Visit:
Steering Committee
About Us
Newsletter
Contact
Types
Therapeutics
Congresses
Trials
Expert Opinions
ASH 2020
AML Types
Signaling pathway mutations
Epigenetic modifier mutations
Origin
Chromosomal aberrations
Nucleophosmin mutations
Tumor suppressor mutations
Spliceosome mutations
Transcription factor mutations
Cohesin mutations
View all Types
Lars Bullinger
Scientific Advisory Board Member
Lars Bullinger
Scientific Advisory Board Member
Types
ASXL1
CEBPA
De novo
Epigenetic modifier mutations
FLT3-ITD
FLT3-TKD
IDH1
IDH2
NPM1
RUNX1
Secondary
Therapy-related
TP53
Interventions
Gilteritinib
IDH1 inhibitors
IDH2 inhibitors
Midostaurin
Venetoclax
Events
ASH 2020
EHA 2018
EHA 2020
ESH 2019
ESH 2020
Trials
All
|
0 Articles
|
6 Videos
|
0 Podcasts